Paul Tudor Jones Ardelyx, Inc. Transaction History

Tudor Investment Corp Et Al

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$6.05 - $9.74 $778,320 - $1.25 Million	128,648 New	128,648 $939,000
Q1 2023 May 15, 2023	BUY	$2.68 - $4.79 $118,072 - $211,033	44,057 New	44,057 $211,000
Q1 2019 May 15, 2019	SELL	$1.88 - $3.35 $26,269 - $46,809	-13,973 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$1.66 - $4.16 $29,063 - $72,833	-17,508 Reduced 55.61%	13,973 $25,000
Q3 2018 Nov 14, 2018	SELL	$3.75 - $4.65 $38,133 - $47,285	-10,169 Reduced 24.42%	31,481 $137,000
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $103,304 - $161,936	27,920 Added 203.35%	41,650 $154,000
Q1 2018 May 15, 2018	SELL	$5.05 - $7.9 $14,347 - $22,443	-2,841 Reduced 17.14%	13,730 $69,000
Q4 2017 Feb 14, 2018	SELL	$4.85 - $7.8 $29,192 - $46,948	-6,019 Reduced 26.64%	16,571 $109,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.7 $98,266 - $128,763	22,590	22,590 $127,000

219

141M

1.08M

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $815M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.